Q3 2018 13F Holders as of 9/30/2018
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
120M
-
Number of holders
-
43
-
Total 13F shares, excl. options
-
16.1M
-
Shares change
-
+16.1M
-
Total reported value, excl. options
-
$282M
-
Value change
-
+$282M
-
Number of buys
-
43
-
Price
-
$17.51
Significant Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) as of Q3 2018
43 filings reported holding AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value as of Q3 2018.
Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) has 43 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 16.1M shares
of 120M outstanding shares and own 13.38% of the company stock.
Largest 10 shareholders include Crestline Management, LP (11.5M shares), PERCEPTIVE ADVISORS LLC (1.15M shares), ALLIANCEBERNSTEIN L.P. (818K shares), BlackRock Inc. (471K shares), Vanguard Group Inc (460K shares), Park West Asset Management LLC (394K shares), MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (303K shares), ASCEND CAPITAL, LLC (181K shares), WASATCH ADVISORS INC (145K shares), and BAKER BROS. ADVISORS LP (99.6K shares).
This table shows the top 43 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.